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OBJECTIVES: The aim of this retrospective study was to investigate the results of T-cell large granular lymphocytic
leukemia treatment with fludarabine by assessing the complete hematologic response, the complete molecular
response, progression-free survival, and overall survival.
METHODS: We evaluated the records of six patients with T-cell large granular lymphocytic leukemia who were
treated with fludarabine as a first-, second-, or third-line therapy, at a dose of 40 mg/m2, for three to five days per
month and 6 to 8 cycles.
RESULTS: Of the six patients investigated with T-cell large granular lymphocytic leukemia who were treated with
fludarabine, five (83.3%) were female, and their median age was 36.5 years (range 18 to 73). The median lymphocyte
level was 3.46109/L (0.5 to 8.9). All patients exhibited a monoclonal T-cell receptor gamma gene rearrangement at
diagnosis. Two (33.3%) patients received fludarabine as first-line treatment, two (33.3%) for refractory disease, one
(16.6%) for relapsed disease after the suspension ofmethotrexate treatment due to liver toxicity, and one (16.6%) due
to dyspesia. A complete hematologic response was achieved in all cases, and a complete molecular response was
achieved in five out six cases (83.3%). During a mean follow-up period of 12 months, both the progression-free
survival and overall survival rates were 100%.
CONCLUSION: T-cell large granular lymphocytic leukemia demonstrated a high rate of complete hematologic and
molecular response to fludarabine, with excellent compliance and tolerability rates. To confirm our results in this
rare disease, we believe that fludarabine should be tested in clinical trials as a first-line treatment for T-cell large
granular lymphocytic leukemia.
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INTRODUCTION
T-cell large granular lymphocytic (T-LGL) leukemia is
characterized by a monoclonal expansion of CD3-positive T-
LGL cells, as described in 1975 (1). This rare and indolent
disorder represents 2% to 3% of chronic lymphoid leukemia
cases, with a median age at diagnosis of 60 years and an
equal male to female ratio (2). The diagnostic criterion is a
persistent increase in circulating monoclonal large granular
lymphocytes lasting at least six months. The neoplastic cells
are CD3, CD8 and TCRab in 80% of cases, but they may be
CD4-CD8-, CD4+CD8- or CD4+CD8+ in rare variants of the
disorder. The associated natural killer cell antigens (NKa)
CD16, CD56 and CD57 are variably expressed; CD57 is the
most commonly expressed cell antigen and CD56 is the least
commonly expressed cell antigen. A total or partial lack of
other T-cell antigens, such as CD2, CD5 and CD7, can be
observed (3-4).
T-LGL leukemia is associated with autoimmune disor-
ders, such as rheumatoid factor with or without rheumatoid
arthritis, Felty’s syndrome, Coombs-positive hemolytic
anemia, idiopathic thrombocytopenic purpura, pure red
cell aplasia, the presence of positive anti-nuclear antibodies,
the presence of anti-neutrophil cytoplasmic antibodies,
hypogammaglobulinemia, and polyclonal hypergammaglo-
bulinemia. Anemia and neutropenia are frequent (5). At
diagnosis, 70% of patients require treatment, but a watch-
and-wait approach may be appropriate for asymptomatic
patients (2). The most common indications for treatment are
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cytopenia, recurrent infection and pure red cell aplasia,
progressive splenomegaly and B symptoms (5).
There is currently no gold standard treatment for T-LGL
leukemia. Most patients are treated with low doses of
methotrexate, cyclophosphamide, and cyclosporine-A. As a
rule, the treatment should be continuously monitored and,
if necessary, adjusted to maintain the desired response.
However, treatment compliance is frequently low, with a
consequent relapse of the disease. Moreover, side effects are
common and may limit the treatment effectiveness (6-7). We
therefore changed our approach to treating T-LGL leukemia
in an attempt to improve the hematological and molecular
response rates and to reduce the treatment duration.
Previous studies have shown promising results with
fludarabine (8), 29-deoxycoformycin and alemtuzumab in
T-LGL leukemia, with a response rate of 40% to 60% when
used as second-line therapy (9). Based on our long-term,
positive experience with fludarabine in other hematological
disorders and in view of the high cost and toxicity of
alemtuzumab, we changed our treatment approach to T-
LGL leukemia by adopting fludarabine as the drug of
choice. Herein, we report our experience using fludarabine
in the treatment of six patients with T-LGL leukemia.
PATIENTS AND METHODS
Patients and end points
This study was a retrospective analysis of data obtained by
reviewing the medical records of six patients with T-LGL
leukemia. They were treated with fludarabine by the same
Hematology Service of the Clinical Hospital of Sa˜o Paulo and
Cancer Institute (Sa˜o Paulo, Brazil) from January 2007 to
January 2009 and February 2009 to October 2010, respectively.
The primary and secondary end points were complete
hematologic (CHR) and complete molecular (CMR)
response and progression-free (PFS) and overall survival
(OS), respectively.
Diagnostic criteria for T-LGL leukemia
The diagnostic criterion for T-LGL leukemia was a
persistent (at least six months) increase in circulating T-
LGL cells, as evaluated by cell morphology and phenotype
and confirmed by a monoclonal T-cell receptor (TCR) gamma
gene rearrangement. A complete blood cell count, peripheral
blood (PB) slide examination, and phenotype determination
by flow cytometry were carried out using a standard
multiparameter methodology to assess the antigens CD2,
CD3, CD4, CD5, CD7, CD8, CD56, CD16, CD58, TCRb, and
TCRcd, as previously described (10). The equipment used
was a FACSCalibur flow cytometer (Becton Dickinson, San
Jose, CA) and the CellQuestPro software. For analysis, the
lymphocyte region was delimitated by an electronic gate in
the forward side scatter versus side scatter display.
Populations of T-LGL cells were defined by the co-expression
of the T-cell CD3 antigen and at least one NKa CD57, CD16 or
CD56 antigen. The normal range of T-LGL cell numbers
assumed in the analysis was 0.1-0.36109/L (11).
T-cell monoclonality assessment
The monoclonal rearrangement of the TCR gamma gene
was assessed by polymerase chain reaction (PCR) using
primer sequences, as described previously by Shadrach B
and Warshawsky I (12). Briefly, each 25-ml PCR reaction
contained 200 ng of DNA, 1.5 U of Taq, 1.5 nmol/L of
MgCl2, 0.2 nmol/L of dNTP, and 0.5 mmol/L of each primer
(IDT Technologies, Illinois, USA). PCR was performed in a
PTC-100 DNA Engine Tetrad (MJ Research, Inc., Waltham,
MA) with one cycle at 94 C˚ for three min, followed by 40
cycles at 95 C˚ for 60 sec, 61.8 C˚ for 30 sec, and 72 C˚ for
30 sec, with a final extension of 10 min at 72 C˚ and then
held at 4 C˚. A 0.1-mL aliquot of the PCR product was mixed
with 12 mL of deionized formamide and 0.5 mL of GeneScan
500 HD Rox size standard (Applied Biosystems, Foster City,
CA). Then, the mixture was injected into an ABI Prism 3130
Genetic Analyzer, and the resulting data were analyzed
using the GeneMapper V 3.2 software (Applied Biosystems,
Foster City, CA). A monoclonality spike was determined by
visual examination of the electropherograms (12).
Treatment
Patients with T-LGL were treated with fludarabine if they
presented with B symptoms, progressive splenomegaly,
recurrent infection or anemia. Fludarabine was used as a
first-line treatment or salvage therapy. HIV-positive patients
were excluded from the study.
Fludarabine was used at a dosage of 40 mg/m2/day path-
way oral for three to five days monthly for 6/8 cycles.
Granulocyte colony-stimulating factor was given to all patients
beginning from the 10th day of each cycle until the end of the
cycle, and it was given for five days if the neutrophil count was
less than 1.06109/L because it was not possible to differentiate
between neutropenia secondary to the disease or due to drug
toxicity. Prophylaxis for Pneumocystis jiroveci with trimetho-
prim-sulfamethoxazole was also indicated for all patients.
Assessment of treatment response
The treatment response was evaluated by periodic clinical
assessments, complete blood cell counts and phenotype and
molecular analysis after cycles four, six and eight. CHR was
defined as the complete normalization of blood counts (i.e.,
hemoglobin .120 g/L, platelets .1506109/L, and neutro-
phils .1.56109/L) and the absence of T-LGL cells. Partial
hematologic response (PHR) was defined as an improve-
ment of more than 50% in the complete blood cell count.
CMR was defined as the absence of a monoclonal popula-
tion as assessed by PCR (13).
RESULTS
Clinical features
Five (83.3%) patients were female, and the median patient
age was 36.5 years (18 to 73) (Table 1). The median
lymphocyte level was 3.46109/L (0.5 to 8.9), with a median
T-LGL cell number of 2.26109/L (0.4-5.3). The median
neutrophil count was 0.356109/L (0.2-0.8). Five (83.3%)
patients had anemia, with a median hemoglobin level of
105 g/L (38-143); two patients (33.3%) presented with pure
red cell aplasia, and the disease was associated with Felt’s
syndrome in two patients (33.3%) (Table 1). Four (66.6%)
patients were CD3+CD8+TCRab+, one (16.6%) was CD4+
CD8-TCRab+, and one (16.6%) was CD4-CD8-TCRcd+. Five
(83.3%) patients were CD57+CD16+, and none of them were
CD56+. All patients were positive for the monoclonal TCR
gamma gene rearrangement.
Two (33.3%) patients received fludarabine as first-line
treatment, another two (33.3%) for refractory disease, one
(16.6%) for relapse disease after discontinuing methotrexate
treatment due to liver toxicity, and one (16.6%) due to
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dyspesia. The most common sign of toxicity was grade 4
neutropenia without infection.
CHR was achieved in all cases, and CMR was achieved in
five out of the six patients (83.3%) (Figure 1). No case of
hematological relapse occurred within a median follow-up
time of 12 months. All patients are still alive. Bone marrow
transplantation was not performed after the treatment with
fludarabine because T-LGL is an indolent disease and is
associated with a high rate of mortality and morbidity.
DISCUSSION
Herein, we describe our experience concerning T-LGL
leukemia treatment with fludarabine. We observed a high
rate of CHR and CMR, with good compliance and minimal
side effects. Because T-LGL leukemia is a rare disease,
prospective, randomized studies to evaluate different treat-
ment protocols are not feasible. Therefore, the treatment of T-
LGL leukemia is based on the findings of case reports and
retrospective studies (14-15). Thus, until 2006, cyclosporine
and methotrexate were the only first-line therapy options for
T-LGL leukemia. Although effective, maintenance therapy is
required to achieve sustained responses with these drugs.
However, maintenance therapy results in significant side
effects, especially in younger patients (7,14,15). In fact, in our
institutions, the median age of T-LGL leukemia patients was
less than described in the literature. Therefore, a short time of
therapy could certainly produce better results because it
avoids adverse events. Although indolent diseases, such as T-
LGL leukemia, require a long follow-up period for the
treatment to lead to a better overall survival, our experience
showed that with cyclosporine-A and methotrexate, only a
minority of patients were able to achieve better results, due to
low compliance rates and drug toxicity.
Fludarabine has been used to treat malignant lymphoid
disorders since the 1990s (16) and has shown high efficacy in
indolent diseases, such as chronic lymphocyte leukemia and
non-Hodgkin lymphoma. In 1994, Witzig et al. (17) described
a case of T-LGL leukemia with transfusion-dependent
anemia that was successfully treated with four cycles of
fludarabine after a seven-year history of partial response to
several drugs. This patient became transfusion-free, with a
partial molecular response lasting more than 15 months.
Another study showed CHR in four symptomatic patients
treated with fludarabine but with no CMR (8). In another
report including 26 patients (14), 19 (73%) were treated with
different drugs, either alone or in combination, such as
cyclosporine-A, erythropoietin, granulocyte colony-stimulat-
ing factor, prednisone, alemtuzumab, pentostatin, fludara-
bine, cyclophosphamide and infliximab, in addition to
splenectomy and hematopoietic stem cell transplantation.
Cyclosporine-A was the most commonly used drug; six
patients achieved CHR, but none of them achieved immu-
nophenotype CR or CMR. Although the authors reported an
absence of response in two patients treated with fludarabine,
they had been previously treated at another institution and
laboratory data were not available to confirm the diagnosis.
In contrast, the best results concerning CMR in T-LGL
leukemia were reported in patients treated with fludarabine,
mitoxantrone and dexamethasone (18). Based on this study,
we decided to use fludarabine to treat our T-LGL leukemia
patients. Our results demonstrated a high rate of CHR and
Table 1 - Clinical Characteristics of Patients.
Patient Age/gender Presentation Hemoglobin (g/L) Lymphocytes (x 109/L) Neutrophils (x 109/L)
Platelets
(x 109/L)
1 54/F Felty’s syndrome 143 1.8 0.3 147
2 45/M Infection 117 3.9 0.4 319
3 73/F Felty’s syndrome 129 0.5 0.2 245
4 25/F Infection 105 8.9 0.8 202
5 28/F PRCA 38 1.6 0.8 147
6 18/F PRCA 69 3.4 0.3 172
F = Female; M = Male; PRCA = pure red cell aplasia.
Figure 1 - Peripheral blood of patient 4: (A) at diagnosis, showing T-cell receptor gamma gene monoclonal rearrangement; and (B)
after eight cycles of fludarabine, showing that the monoclonal cells were completely replaced by polyclonal T-cells, which is
characteristic of a complete molecular response (CMR).
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CMR, along with excellent treatment compliance and drug
tolerance. In accordance with the literature, our main indica-
tion for treatment was cytopenia and recurrent infection (19).
In our series of cases, we found a high rate of CHR and
CMR with fludarabine, along with excellent compliance and
tolerability. Even though our number of cases was small, we
suggest that fludarabine should be further tested as a first-
line treatment option for T-LGL to confirm these prelimin-
ary data.
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